Singvarin

Singvarin is a synthetic antimalarial drug that was developed in the 1960s. It is a 4-aminoquinoline derivative and acts by inhibiting the enzyme dihydrofolate reductase, which is essential for the synthesis of folic acid in the malaria parasite. This interruption in the parasite's metabolism leads to its death.

Singvarin was initially used as a single agent for the treatment of malaria, but its efficacy was limited due to the development of resistance in the parasite. It is now primarily used in combination therapy with other antimalarials, such as chloroquine or sulfadoxine-pyrimethamine, to improve its effectiveness and delay the onset of resistance.

The drug is typically administered orally and is well-tolerated, with common side effects including nausea, vomiting, and abdominal pain. More severe side effects are rare but can include hemolytic anemia and thrombocytopenia.

Singvarin is not available in many countries due to its limited efficacy and the availability of more effective treatments. However, it remains an important historical and scientific reference in the field of antimalarial drug development.

Research into singvarin has contributed to the understanding of the mechanisms of action of antimalarial drugs and has influenced the development of new treatments.